|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results show that fingolimod induces BAFF in the circulation and expands transitional B cells, but does not activate memory B cells or plasma cells in MS, which is favorable for the treatment of this disease.
|
29079163 |
2018 |
|
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An insertion-deletion variant (GCTGT→A) of this gene, leading to increased levels of BAFF, has been recently implicated in the genetic predisposition to several autoimmune diseases, including multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.
|
30586461 |
2018 |
|
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A rare variant (BAFF-var) of the tumor necrosis factor superfamily 13b (TNFSF13B) gene has been recently associated with multiple sclerosis (MS) and systemic lupus erythematosus (SLE).
|
29844438 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A variant in TNFSF13B, encoding the cytokine and drug target B-cell activating factor (BAFF), was associated with multiple sclerosis as well as SLE.
|
28445677 |
2017 |
|
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset.
|
28095856 |
2017 |
|
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To evaluate serum levels of CXCL13 and BAFF in NMO and multiple sclerosis (MS) patients during remission and explore their correlation with immunosuppressive agents and clinical features in NMO.
|
28413701 |
2017 |
|
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BAFF and APRIL levels in the CSF were significantly higher in patients with ANCA-HP than in those with MS and NIND.
|
28847534 |
2017 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we further discuss evidence for B cell and Ig contribution to human MS and NMO pathogenesis, pro-inflammatory and regulatory B cell effector functions, impaired B cell immune tolerance, the B cell-fostering microenvironment in the CNS, and B cell-targeted therapeutic interventions for MS and NMO, including CD20 depletion (rituximab, ocrelizumab, and ofatumumab), anti-IL6-R (tocilizumab), complement-blocking (eculizumab), inhibitors of AQP4-Ig binding (aquaporumab, small molecular compounds), and BAFF/BAFF-R-targeting agents.
|
24832354 |
2014 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.
|
19763798 |
2010 |
|
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation.
|
20535037 |
2010 |
|
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum BAFF levels were examined by an enzyme-linked immunosorbent assay (ELISA) in 42 patients with BD (16 with active disease), 20 healthy controls, and in 20 patients with systemic lupus erythematosus (SLE) and 15 patients with multiple sclerosis (MS), who served as the disease control groups.
|
19026118 |
2009 |
|
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BAFF and BAFF-R expression in CSF were increased in NBD and MS patients compared to NIND patients.
|
18625522 |
2008 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
BAFF is a biological response marker to IFN-beta treatment in multiple sclerosis.
|
18715196 |
2008 |